1
Acorda Therapeutics CEO: High-Powered Biotech | Mad Money | CNBC
Acorda Therapeutics CEO: High-Powered Biotech | Mad Money | CNBC
DATE: 2015/01/12::
2
Syncplicity Customer Success Program | Driving User Adoption at Acorda Therapeutics
Syncplicity Customer Success Program | Driving User Adoption at Acorda Therapeutics
DATE: 2014/10/07::
3
Spotlight - Acorda Therapeutics - Bloomberg
Spotlight - Acorda Therapeutics - Bloomberg
DATE: 2009/07/01::
4
Ron Cohen, President and CEO of Acorda Therapeutics, Inc.
Ron Cohen, President and CEO of Acorda Therapeutics, Inc.
DATE: 2012/02/16::
5
News Update: Acorda Therapeutics (NASDAQ:ACOR) announce Ampyra Pricing
News Update: Acorda Therapeutics (NASDAQ:ACOR) announce Ampyra Pricing
DATE: 2010/02/08::
6
Acorda Therapeutics 100% virtualized environment
Acorda Therapeutics 100% virtualized environment
DATE: 2012/11/05::
7
Acorda Therapeutics CEO Ron Cohen, MD takes the ALS ice bucket challenge
Acorda Therapeutics CEO Ron Cohen, MD takes the ALS ice bucket challenge
DATE: 2014/08/15::
8
Syncplicity Success Story | Acorda Therapeutics
Syncplicity Success Story | Acorda Therapeutics
DATE: 2015/01/15::
9
Acorda Therapeutics Prints Unexpected Profit As Sales Jump 318%
Acorda Therapeutics Prints Unexpected Profit As Sales Jump 318%
DATE: 2010/11/01::
10
Acorda Therapeutics, Inc - 2014 Small Business Award
Acorda Therapeutics, Inc - 2014 Small Business Award
DATE: 2014/04/29::
11
Acorda Therapeutics Disaster Recovery Strategy with VMware SRM
Acorda Therapeutics Disaster Recovery Strategy with VMware SRM
DATE: 2012/11/05::
12
Acorda Therapeutics
Acorda Therapeutics
DATE: 2013/03/17::
13
Earnings Report: Acorda Therapeutics (NYSE:ACOR) Reports Inline Loss, Top Line Up 15.9%
Earnings Report: Acorda Therapeutics (NYSE:ACOR) Reports Inline Loss, Top Line Up 15.9%
DATE: 2010/02/23::
14
Acorda Therapeutics Reported Mixed Q4 Results
Acorda Therapeutics Reported Mixed Q4 Results
DATE: 2011/02/17::
15
Technical Analysis: After Yesterday
Technical Analysis: After Yesterday's Rally of 4.27%, Acorda Therapeutics Shares Could Pullback
DATE: 2010/05/13::
16
Acorda Therapeutics on EMC VSPEX
Acorda Therapeutics on EMC VSPEX
DATE: 2013/09/09::
17
"Bearish Moving Average Cross by Acorda Therapeutics "
"Bearish Moving Average Cross by Acorda Therapeutics "
DATE: 2011/02/04::
18
Acorda Therapeutics Missed Q2 Estimates, Top Line Up Nearly 53% YoY
Acorda Therapeutics Missed Q2 Estimates, Top Line Up Nearly 53% YoY
DATE: 2011/08/01::
19
Acorda Therapeutics (NASDAQ:ACOR) Stock Trading Idea: 15.6% Return in 3 Months
Acorda Therapeutics (NASDAQ:ACOR) Stock Trading Idea: 15.6% Return in 3 Months
DATE: 2010/01/25::
20
Acorda Therapeutics Inc Stock Rises on Civitas Acquisition
Acorda Therapeutics Inc Stock Rises on Civitas Acquisition
DATE: 2014/09/25::
21
Acorda
Acorda's Cohen Sees Demand Growth for MS Drug Ampyra: Video
DATE: 2012/03/23::
22
Acorda Shares Drop on European Regulators
Acorda Shares Drop on European Regulators' Rejection of MS Drug
DATE: 2011/01/21::
23
WESEF 2105 montage for YouTube
WESEF 2105 montage for YouTube
DATE: 2015/03/10::
24
Acorda Shares Drop on European Regulators
Acorda Shares Drop on European Regulators' Rejection of MS Drug
DATE: 2011/01/21::
25
rHigM22: A Novel Investigational Compound to Enhance Remyelination in the CNS
rHigM22: A Novel Investigational Compound to Enhance Remyelination in the CNS
DATE: 2013/12/20::
26
Cohen Says Acorda Is Looking to Develop New Drugs
Cohen Says Acorda Is Looking to Develop New Drugs
DATE: 2011/06/27::
27
Acorda Falls Back to Earth Following Monday Gains, Shares Slide 8%
Acorda Falls Back to Earth Following Monday Gains, Shares Slide 8%
DATE: 2011/01/12::
28
Working2Walk2011, Anthony Caggiano
Working2Walk2011, Anthony Caggiano
DATE: 2012/09/02::
29
Being Money Smart - Financial Wellness Webinar Series
Being Money Smart - Financial Wellness Webinar Series
DATE: 2012/09/06::
30
SCI Hall of Fame 2007, Part 11
SCI Hall of Fame 2007, Part 11
DATE: 2007/11/30::
31
Technical Analysis Review of the Stock Market 10/03/06
Technical Analysis Review of the Stock Market 10/03/06
DATE: 2006/10/03::
32
Technical Analysis Review of the Stock Market 10/02/06
Technical Analysis Review of the Stock Market 10/02/06
DATE: 2006/10/02::
33
Technical Analysis Review of the Stock Market 10/4/06
Technical Analysis Review of the Stock Market 10/4/06
DATE: 2006/10/04::
34
Chart of the Day  - ACOR, EXXI, MNTA, RXi - Harry Boxer, TheTechTrader.com
Chart of the Day - ACOR, EXXI, MNTA, RXi - Harry Boxer, TheTechTrader.com
DATE: 2010/02/01::
35
The latest in stem cell medicine | Mark Noble | TEDxRochester
The latest in stem cell medicine | Mark Noble | TEDxRochester
DATE: 2012/04/02::
36
Pre-Market Movers: January 21st, 2011
Pre-Market Movers: January 21st, 2011
DATE: 2011/01/21::
37
Bryan Glazer World Satellite Television News FAMPRIDINE SPINAL INJURY RX ELECTRONIC PRESS KIT
Bryan Glazer World Satellite Television News FAMPRIDINE SPINAL INJURY RX ELECTRONIC PRESS KIT
DATE: 2014/02/05::
38
Ron Cohen - 2012 Burke Award Winner
Ron Cohen - 2012 Burke Award Winner
DATE: 2012/06/27::
39
2014 New York SmartCEO EMA Awards - CXO
2014 New York SmartCEO EMA Awards - CXO
DATE: 2014/04/30::
40
Passfail.com News: PCY, BIB: Big ETF Inflows
Passfail.com News: PCY, BIB: Big ETF Inflows
DATE: 2012/10/05::
41
2014 New York SmartCEO EMA Awards - CIO, CTO and COO
2014 New York SmartCEO EMA Awards - CIO, CTO and COO
DATE: 2014/04/30::
42
2014 New York SmartCEO EMA Awards - CFO
2014 New York SmartCEO EMA Awards - CFO
DATE: 2014/04/30::
43
Plenary - Who Will Pay for Tomorrow
Plenary - Who Will Pay for Tomorrow's Medical Breakthroughs?
DATE: 2011/11/08::
44
Left ventricular dysfunction pipeline assessment unveils a promising future
Left ventricular dysfunction pipeline assessment unveils a promising future
DATE: 2015/05/28::
45
Pre Market Movers: May 20, 2011
Pre Market Movers: May 20, 2011
DATE: 2011/05/20::
46
The Multiple Sclerosis Therapy Market is on the Verge of an Overhaul
The Multiple Sclerosis Therapy Market is on the Verge of an Overhaul
DATE: 2012/06/19::
47
CLDX, FSLR, CYBX, RNF -- Stock Charts - Harry Boxer, TheTechTrader.com
CLDX, FSLR, CYBX, RNF -- Stock Charts - Harry Boxer, TheTechTrader.com
DATE: 2013/04/16::
48
The Fly On The Wall Market Snapshot: Feb 4, 2010
The Fly On The Wall Market Snapshot: Feb 4, 2010
DATE: 2010/02/04::
49
Sarcastic - Glorious... Acorda
Sarcastic - Glorious... Acorda
DATE: 2011/04/28::
50
Mãe acorda filho para não perde a hora da aula, Muleque surta!
Mãe acorda filho para não perde a hora da aula, Muleque surta!
DATE: 2013/08/14::
NEXT >>
RESULTS [51 .. 101]
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Acorda Therapeutics Inc.
Public
Traded as NASDAQACOR FWBCDG
Industry Health care
Biotechnology
Founded 1995 (1995)[1]
Founder Ron Cohen
Headquarters Ardsley, New York, United States
Key people
Ron Cohen
Andrew R. Blight
Products Zanaflex
Ampyra
Qutenza
Revenue Increase US$292.2 Million (FY 2011)[2]
Increase US$35.1 Million (FY 2011)[2]
Increase US$30.6 Million (FY 2011)[2]
Total assets Increase US$379.5 Million (FY 2011)[2]
Total equity Increase US$205.2 Million (FY 2011)[2]
Number of employees
328 (February, 2012) [2]
Website Acorda.com

Acorda Therapeutics is a biotechnology company based in Ardsley, New York, USA. The company develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system.[3] Acorda manufactures and markets the drugs Zanaflex, Ampyra and Qutenza in the United States.

History[edit]

Corporate governance[edit]

As of December 31, 2013, the members of the board of directors of Acorda Therapeutics were:[4] Ron Cohen, Barry Greene, Peder K. Jensen, John P. Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, and Ian F. Smith.

Products[edit]

Products on the market[edit]

Products under development[edit]

References[edit]

External links[edit]


Wikipedia content is licensed under the GFDL License
Powered by YouTube
MASHPEDIA
LEGAL
  • Mashpedia © 2015